Hepatitis B Trial, Recruiting NCT06779058 Sponsor: Shengjing Hospital Condition: Hepatitis B
Back to Hepatitis B

Hepatitis B Trial, Recruiting

NCT06779058
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older
  • You must have a confirmed diagnosis of chronic hepatitis B, confirmed through blood tests, imaging, and clinical examination
  • You must have had a specific liver imaging scan called MRE (magnetic resonance elastography) within 6 months before or after a liver biopsy
  • You must not have previously received treatment for hepatitis B
  • Your liver function must be at a relatively healthy level, measured by a scoring system called Child-Pugh Grade A (fewer than 7 points) (confirm with trial site)
  • You must be willing to sign a written consent form if joining the follow-up part of the study

Who may not be able to join:

  • You cannot join if you have a cancerous (malignant) tumor in your liver
  • You cannot join if your liver disease is caused by something other than hepatitis B, such as alcohol-related liver disease
  • You cannot join if you have hepatitis B alongside hepatitis C, hepatitis D, or HIV
  • You cannot join if you have a disease affecting your bile ducts or gallbladder
  • You cannot join if you are unable to have an MRE scan for any reason, or if the MRE scan does not produce usable results
  • You cannot join if the tissue sample taken from your liver biopsy is not of sufficient quality for analysis (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yu Shi, Shengjing Hospital

Phone: +86 15291014907

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Accuracy of the features of MRE for grading fibrosis in chronic hepatitis B.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov